Table of Contents

Preface; FIRST LINE ANTI-INFLAMMATORY AND BRONCHODILATOR DRUGS; 1. Novel mechanistic aspects of GCS in relation to asthma therapy. I Adcock; 2. Benefit-risk of long-acting [beta]-adrenergic and ultra long-acting [beta]-adrenergic agonists. M Cazzola, J Lotvall, MG Matera; 3. Non-bronchodilator activities of beta2-agonists: enhanced efficacy in the management of asthma? N Hanania; 4. The pros and cons of combination therapy. J Lotvall; NOVEL APPROACHES TO BRONCHODILATION; 5. Controversies on antileukotrienes. S Salvi; 6. Role of PDE4 in asthma. G Currie; 7. Anti-cholinergics in asthma? C Virchow; IMMUNOMODULATION; 8. The new role of anti-IgE therapy in the treatment of asthma. C Oliveri, R Polosa, G D'Amato; 9. Life, death and resurrection of allergen immunotherapy in asthma. R Polosa; 10. Role of CpG DNA in asthma. D Gor, J Kline; 11. Putative role of antimicrobial activity in asthma treatment. P Tarsia, S Aliberti, M Pappalettera, M Zanardelli, F Blasi; SUBPHENOTYPE CENTERED THERAPY; 12. What is new in the management of acute asthma? GJ Rodrigo; 13. Rethinking individualized treatment of asthma. FE Hargreave; 14. Determinants of therapeutic response in asthma: cigarette smoking. M Spears, R Chaudhuri, NC Thomson; Abbreviations; General Index.

About the Author

R Polosa, Presidio Ospedaliero Ascoli-Tomaselli, Catania, Italy ST Holgate, Southampton General Hospital, Southampton, UK